Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Philips Introduces Mobile C-arm With Flat Detector For Surgical X-ray Procedures
With rapid change taking place in the surgical environment as the range of interventional and minimally invasive procedures continues to expand, Royal Philips Electronics (AEX: PHI, NYSE: PHG) today announced the availability of the Veradius X-ray system. A mobile C-arm with a super thin, flat detector, Philips Veradius is designed to give the surgeon more flexibility and to improve patient care by streamlining workflow and improving image quality. The system also includes an additional monitor on the C-arm stand, enabling the operator to have an unobstructed view of the live image.
generic viagra online
The Cost Of Autism In The UK Is More Than $41 Billion Every Year
Research published this week in the journal Autism, published by SAGE, estimate the annual costs of autism spectrum disorder (ASD) to be more than ÷£27 billion a year. The costs of supporting children with ASDs were estimated to be ÷£2.7 billion per year, ÷£25 billion each year for adults. The findings were presented at the Autism & Employment Workshop at Goldsmiths, University of London.
News of the day
King Provides Additional Information On The REMOXY(R) NDA Resubmission Plan
King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY(R) New Drug Application (NDA). The Company is not required by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate-to-severe chronic pain. However, as part of the resubmission plan, and in order to strengthen the NDA, King plans to conduct a likeability study and a pharmacokinetic trial in volunteers. The Company continues to anticipate the resubmission could occur mid-year 2010.
Public Health

A Catalyst For Public Debate: Promoting Openness, Full Disclosure, And Accountability

An independent large study conducted by MEDCO Health Solutions Inc. found that women treated with tamoxifen for breast cancer doubled the risk of the disease returning if they used antidepressants--in particular, Paxil and Prozac. The researchers used medical records to identify 353 women taking tamoxifen plus other drugs that might interfere with it, and 945 women taking tamoxifen alone. Those taking a drug combo did so for about a year on average. Next, researchers checked to see how many were treated for second cancers in the following two years. "Breast cancer recurred in about 7 percent of women on tamoxifen alone, and in 14 percent of women also taking the antidepressants Paxil and Prozac, and, to a lesser extent, Zoloft." Medco"s chief medical officer, Dr. Robert Epstein, said: If women want to take an antidepressant, "you probably want to stay away from those three." Alliance For Human Research Protection


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009